Raltegravir is an integrase inhibitor. Its role is to block an enzyme that retroviruses use to insert their genetic material into host cells. This mechanism is the reason veterinary researchers became interested in raltegravir for cats: feline leukemia virus FeLV is also a retrovirus, so inhibiting integration may help reduce viral activity.

Published veterinary studies have evaluated raltegravir in FeLV-positive cats. Some reports describe good tolerance and a reduction in viral load while treatment is being given. However, this should not be understood as a guaranteed cure. Viral activity may return after treatment is stopped, and long-term evidence in cats is still limited.

It is important to treat this as a veterinary decision, often involving off-label use of a human medicine. Raltegravir should not be given to a cat without professional supervision. The dose, treatment duration, blood monitoring, liver and kidney checks, and compatibility with other medicines must be assessed by a veterinarian who knows the individual animal.

Why do owners ask about Ralmac-400? Ralmac-400 contains raltegravir 400 mg, so it may be discussed as a source of the active ingredient when a veterinarian specifically prescribes raltegravir. Still, the tablet is not designed for cats, and any use requires professional dose calculation and monitoring. The information on this website is for reference only and is not a substitute for veterinary advice.